La Jolla Pharmaceutical Company acquires Tetraphase Pharmaceuticals and with it Xerava
La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline Xerava to treat serious and life-threatening infections, announced that they have entered into a definitive merger agreement.